Bioallethrin

Summary

Bioallethrin (CHEMBL1788403) is an approved small molecule (ATC P03AC52); indicated across 1 condition including parasitic infectious disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: P03AC52 (+1 more)
• Indications: 1 condition
• Chemistry: 302.4 Da · C19H26O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1788403
Name	Bioallethrin
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	15558638
ChEBI	CHEBI:143255
ATC	P03AC52, P03AC02
Molecular formula	C19H26O3
Molecular weight	302.4
InChIKey	ZCVAOQKBXKSDMS-AQYZNVCMSA-N

SMILES: CC1=C(C(=O)CC1OC(=O)[C@@H]2[C@H](C2(C)C)C=C(C)C)CC=C

IUPAC name: cis-(2-methyl-4-oxo-3-prop-2-enylcyclopent-2-en-1-yl) (1R,3R)-2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropane-1-carboxylate

ChEBI definition: A partly enantiopure variant of allethrin consisting of a mixture of two allethrin isomers (1R,trans;1R and 1R,trans;1S) in an approximate ratio of 1:1. Widely registered mosquito adulticide and spatial repellent. Bioallethrin is a synthetic pyrethroid used as a pesticide against household pest insects such as mosquitoes, houseflies and cockroaches.

Also known as: Allethrin, Allethrin i, Bioallethrin, Depallethrin, Esbiothrin, NSC-11782, Pynamin, Trans-allethrin, BIOALLETHRIN

Patent coverage: 385 distinct patent families (783 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
parasitic infectious disease	4	MONDO:0005135	EFO:0001067

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).